Table 6. Target INR for heart valve prostheses from other guidelines.

From ACC/AHA Pocket Guidelines. Management of Patients With Valvular Heart Disease. July 2000.

.	INR 2.0-3.0	INR 2.5-3.5	ASA 80-100
MECHANICAL PROSTHETIC VALVES	.
A. First 3 months after replacement	.	+	+
B. After first 3 months:	.	.	.
--1. Aortic valve*	+	.	+
--2. Aortic valve + risk factor**	.	+	+
--3. Mitral valve	.	+	+
--4. Mitral valve + risk factor**	.	+	+
BIOLOGICAL PROSTHETIC VALVES	.
A. First 3 months after replacement	.	+	+
B. After first 3 months:	.	.	.
--1. Aortic valve*	.	.	+
--2. Aortic valve + risk factor†	+	.	+
--3. Mitral valve	.	.	+
--4. Mitral valve + risk factor†	.	+	+

• Based on McAnulty JH, Rahimtoola SH, Antithrombotic therapy in valvular heart disease. In Schlant R, Alexander RW, eds. Hurst's The Heart, Arteries, and Veins. 9th ed. New York, NY: Mcgraw-Hill Publishing Co; 1998: 1867-1874.
• Notice the new recommendation of adding ASA 80-100 mg. to all patients with mechanical heart valve prostheses.
• * = St. Jude Medical bileaflet, CarboMedics bileaflet, Medtronic-Hall tilting mono disc, Omnicarbon mono tilting disc, and Sorin bileaflet. For other aortic protheses INR should be maintain between 2.5-3.5.
• ** = Risk factors: Atrial fibrillation, severe LV systolic dysfunction, recurrent CHF, previous thromboembolism, and hypercoagulable conditions.